N/A
Completed N=1,826
Agrylin Drug Use-Result Survey
Essential Thrombocythemia (ET)
Source: ClinicalTrials.gov NCT03625895 ↗
Enrolled (actual)
1,826
Serious AEs
18.9%
Results posted
Feb 2023
Primary outcomePrimary: Number of Participants Who Had One or More Adverse Events — 776 Participants
Summary
The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Had One or More Adverse Events |
776 | — |
| PRIMARY Number of Participants Who Had One or More Serious Adverse Event |
234 | — |
| PRIMARY Number of Participants Who Had One or More Adverse Drug Reactions |
628 | — |
| PRIMARY Number of Participants Who Had One or More Serious Adverse Drug Reactions |
100 | — |
| PRIMARY Percentage of Participants Who Responded in Platelet Count |
61.02 | — |
| PRIMARY Percentage of Participants With Normalization in Platelet Count |
28.97 | — |
| SECONDARY Percentage of Participants With at Least 50% Reduction in Platelet Count |
38.90 | — |
Eligibility Criteria
Inclusion Criteria
- All cases who received treatment with Agrylin.
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT03625895). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.